Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
Polyrizon Ltd. - Ordinary Shares (PLRZ)
Company Research
Source: GlobeNewswire
Raanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an accepted and standard comparator used in nasal barrier products. The study, conducted using a validated in-vitro Transwell permeability system designed to mimic allergen transfer into the nasal mucosa, assessed PL-14’s ability to inhibit transfer of Der p 1, a major clinically relevant house dust mite allergen commonly associated with allergic rhinitis and asthma. Key findings demonstrated that PL-14 significantly reduced allergen transfer at all time points compared with HPMC, including early time points that are considered critical for preventing allergen-trigg
Show less
Read more
Impact Snapshot
Event Time:
PLRZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRZ alerts
High impacting Polyrizon Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PLRZ
News
- Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference ProductGlobeNewswire
- Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy BlockerPR Newswire
- Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet OperatorGlobeNewswire
- Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen FormulationGlobeNewswire
- Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company [Yahoo! Finance]Yahoo! Finance
PLRZ
Sec Filings
- 2/26/26 - Form 6-K
- 2/6/26 - Form 6-K
- 2/4/26 - Form 6-K
- PLRZ's page on the SEC website